Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases

Gastric Cancer Clinical Trial

Official title:

Human HER2-targeted Chimeric Antigen Receptor Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases: an Exploratory Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06224738
• Other study ID #: ITT-20231107-0257-02
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: March 1, 2024
• Est. completion date: March 1, 2026

Study information

• Verified date: January 2024
• Source: First People's Hospital of Hangzhou
• Contact: Bing Xia, Doctor
• Phone: (+86)18857210928
• Email: bxia_hzch[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this exploratory clinical trial is to evaluate the safety and efficacy of human anti-human epidermal growth factor receptor 2(HER2) Chimeric antigen receptor macrophage cells (CAR-M) in advanced HER2+ gastric cancer. Participants will mobilize bone marrow stem cells and engineer autologous macrophages to express Chimeric antigen receptor (CAR), and CAR-M will be infused intraperitoneally back into the patient for systemic anti-tumor effects.

Description:

The standard approach for managing advanced peritoneal metastatic gastric cancer typically involves systemic administration of antitumor drugs. In the case of HER2-positive gastric cancer patients, a combination of trastuzumab, platinum, and fluorouracil chemotherapeutic agents is commonly employed. Nevertheless, conventional therapy encounters obstacles stemming from tumor heterogeneity and the intricate microenvironment. The self-developed humanized anti-HER2 chimeric antigen receptor macrophage (human anti-HER2 CAR-M) uses an adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to human HER2 antigens to recognize and kill tumor cells. Cell and animal experiments as well as preclinical trials showed that anti-human HER2 CAR M cells have significant anti-tumor efficacy and good safety. This study can provide abundant clinical data for the safety and feasibility of CAR macrophage therapy for solid tumors, and promote the progress of CAR macrophage therapy for solid tumors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9
• Est. completion date: March 1, 2026
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. age between 18 and 75 years (including borderline values), male or female.

2. expected survival of more than 12 weeks.

3. histologically confirmed HER2-positive gastric cancer; HER2-positive is defined as immunohistochemistry (IHC) 3+ or (IHC) 2+ with in situ hybridization (ISH) +.

4. confirmation of peritoneal metastasis by imaging or cytologic testing of peritoneal fluid.

5. presence of measurable lesions.

6. patients with peritoneal metastases of gastric cancer who had previously failed second-line or higher therapy. Treatment failure is defined as an intolerable toxic reaction or disease progression during treatment or tumor recurrence or metastasis after completion of treatment. Prior therapy of targeted agents, immunosuppressants, or radiotherapy is permitted; prior systemic therapy with at least 1-2 chemotherapeutic agents of fluorouracil, platinum, and paclitaxel in combination with targeted agents.

7. have an Eastern Cooperative Oncology Group (ECOG) activity status score of 0-2

8. at least 2 weeks have elapsed since receiving the most recent drug therapy to the time of single nucleated cell collection.

9. patients of childbearing age are required to use appropriate contraception (protection or other birth control) prior to enrollment and during the study.

10. the patient is willing to accept intraperitoneal administration of the drug.

11. the patient understands the trial and has signed an informed consent form.

12. the patient is able to follow the study protocol and follow-up procedures.

Exclusion Criteria:

1. previous or current other types of malignant tumors, except for the following:

completely resected or eradicated basal and squamous cell carcinoma of the skin, and carcinoma in situ of the cervix.

2. patients requiring immunosuppressive drugs (except physiologic replacement doses).

3. history of central nervous system (CNS) disorders such as seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, psychosis; untreated or symptomatic CNS metastases or cytologically confirmed carcinomatous meningitis (asymptomatic CNS metastases that do not require treatment may be enrolled).

4. left ventricular ejection fraction <50%.

5. White blood cell count <3×10^9/L and platelet count <80×10^9/L.

6. AST and ALT > 3 × upper limit of normal (ULN)

7. Total bilirubin > 1.5 × ULN.

8. creatinine clearance <60 ml/min.

9. Abnormal coagulation function (activated partial thromboplastin time (APTT) > 1.5 × ULN, international normalized ratio (INR) > 1.5 × ULN).

10. patients with intestinal obstruction (gastrointestinal obstruction within 30 days prior to administration).

11. patients with infectious diseases including, but not limited to: 1) known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related disease; 2) known active liver disease, including hepatitis B and hepatitis C; 3) active tuberculosis infection, who are on anti-tuberculosis treatment or who have received anti-tuberculosis treatment within 1 year prior to the first dose of the study drug; 4) known syphilis infections requiring treatment; and 5) Other infectious diseases that, in the judgment of the investigator, make participation in this study unsuitable.

12. Diseases that, in the judgment of the investigator, preclude enrollment: including, but not limited to, severe hepatic, renal, or metabolic disease requiring drug therapy, uncontrolled coronary artery disease or asthma, and uncontrolled cerebrovascular disease.

13. pregnant or breastfeeding females; females or males of childbearing age with a pregnancy plan during the study.

14. psychotropic substance abuse, clinical or psychological or social factors that would compromise informed consent or study conduct (at the discretion of the investigator).

15. individuals who may be allergic to the study medication.

16. is participating in another clinical trial.

17. patients with inaccessible peripheral or deep venous access.

18. any uncertainty that has an impact on patient safety or compliance.

19. any other condition that the investigator considers inappropriate for enrollment.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Biological:
• human HER2-targeted CAR-M cells
The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.

Locations

Country	Name	City	State
China	Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
First People's Hospital of Hangzhou	Macera therapeutics

Country where clinical trial is conducted

China, 

References & Publications (2)

Dong X, Fan J, Xie W, Wu X, Wei J, He Z, Wang W, Wang X, Shen P, Bei Y. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023 Aug;129(3):551-562. doi: 10.1038/s41416-023-02319-6. Epub 2023 Jun 29. — View Citation

Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, Zheng W, Lu Y, Zhang W, Bei Y, Shen P. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019 Nov;121(10):837-845. doi: 10.1038/s41416-019-0578-3. Epub 2019 Oct 1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse effects	Collect information on the type, frequency, and severity of adverse events.Identify and grade adverse events following CTCAE 5.0 criteria.	The evaluation was conducted within 28 days of administration, with a total of 30 recording points
Secondary	Time to Sustained Remission (DOR)	Solid tumor efficacy was assessed following the RECIST 1.1 criteria, calculating the time from first onset of efficacy (i.e., complete remission (CR) or partial remission (PR)), to earliest disease progression or death.	1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months post-infusion.
Secondary	Overall response rate (ORR)	Solid tumor efficacy was assessed following RECIST 1.1 criteria, and the proportion of subjects in complete or partial remission was calculated.	Initiation of the first evaluation of the tumor as CR or PR to the beginning of the -th evaluation as progressive disease (PD) or death from any cause.
Secondary	Disease Control Rate (DCR)	The RECIST 1.1 criteria were followed to assess the efficacy of solid tumors, and DCR was defined as the number of cases that achieved remission (CR+PR) and stable disease (SD) after treatment as a percentage of the number of evaluable cases.	Assessed every month, up to 3 months.
Secondary	Progression-free survival (PFS)	Solid tumor efficacy was assessed following the RECIST 1.1 criteria by calculating the time between infusion and the first record of disease progression or death.	From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary	Overall Survival (OS)	Calculation of time from infusion to death from any cause.	From date of randomization until the date of death from any cause, assessed up to 100 months